Darush Rahmani, DO
Rheumatology · Round Rock, TXNPI 1598714495
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $815 of the $1,040 with a category attached, or 78.4%. 10 manufacturers reported payments, led by UCB, Inc. at 31.3% of the total. Reporting peaked in 2021 at $587 and has fallen 96.5% since, to $20 in 2025. That places this record below the midpoint for rheumatology clinicians in TX, where the typical reported total is $3,779.
Across 68 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$325
- AbbVie$241
- Welch Allyn$186
- Johnson & Johnson$99
- Amgen$87
- GSK$39
- plus $63 from 4 others
Across 39 payments — averaging $13,710 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$515K
- Swing Therapeutics, Inc.$19K
What the payments were for
- Food & beverage$81578%
- Education$394%
- Other$18618%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 23 | $325 |
| AbbVie | 25 | $241 |
| Welch Allyn | 1 | $186 |
| Johnson & Johnson | 7 | $99 |
| Amgen | 6 | $87 |
| GSK | 2 | $39 |
| Radius Health, Inc. | 1 | $24 |
| Pfizer | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,040 in reported general payments places this provider in the 25th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 65 | $591,988 |
| Humira(Cf) PenAdalimumab | 46 | $431,807 |
| Teriparatide | 45 | $119,838 |
| Cosentyx Sensoready PenSecukinumab | 17 | $117,791 |
| KevzaraSarilumab | 27 | $116,205 |
| OtezlaApremilast | 15 | $115,459 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $100,527 |
| Humira(Cf)Adalimumab | 13 | $88,550 |
| ActemraTocilizumab | 31 | $81,439 |
| ForteoTeriparatide | 12 | $49,926 |
| OlumiantBaricitinib | 11 | $29,537 |
| Hydroxychloroquine Sulfate | 267 | $12,192 |
| MethotrexateMethotrexate Sodium | 258 | $9,415 |
| Febuxostat | 29 | $6,599 |
| Mycophenolate Mofetil | 51 | $5,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $87 | $115,45915 claims |
| AbbVieHumira(Cf) | $241 | $88,55013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Round Rock
- John CushDallas$3.7M
- Sanjay ChabraEl Paso$3.3M
- Dhiman BasuColleyville$1.8M
- Frank WellborneNew Braunfels$1.4M
- Christopher ParkerWest Lake Hills$1.4M
- Pendleton WickershamSan Antonio$954K
- Henry TownsendPlano$738K
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.